Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,980 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody.
Shibaki R, Murakami S, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Kusumoto M, Yamamoto N, Ohe Y. Shibaki R, et al. Among authors: yoshida t. Cancer Immunol Immunother. 2020 Jan;69(1):15-22. doi: 10.1007/s00262-019-02431-8. Epub 2019 Nov 19. Cancer Immunol Immunother. 2020. PMID: 31745589 Free PMC article.
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
Niho S, Yoshida T, Akimoto T, Sakamaki K, Ono A, Seto T, Nishio M, Yamamoto N, Hida T, Okamoto H, Kurata T, Satouchi M, Goto K, Yamanaka T, Ohe Y. Niho S, et al. Among authors: yoshida t. Lung Cancer. 2020 Mar;141:64-71. doi: 10.1016/j.lungcan.2020.01.008. Epub 2020 Jan 10. Lung Cancer. 2020. PMID: 31955002 Clinical Trial.
Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.
Shibaki R, Murakami S, Shinno Y, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Yamamoto N, Ohe Y. Shibaki R, et al. Among authors: yoshida t. Cancer Immunol Immunother. 2020 Jul;69(7):1229-1236. doi: 10.1007/s00262-020-02539-2. Epub 2020 Mar 10. Cancer Immunol Immunother. 2020. PMID: 32152703 Free PMC article.
Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Shirasawa M, Yoshida T, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: yoshida t. Eur J Cancer. 2020 Nov;140:28-36. doi: 10.1016/j.ejca.2020.08.028. Epub 2020 Oct 8. Eur J Cancer. 2020. PMID: 33039811
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Murakami S, Shibaki R, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y. Murakami S, et al. Among authors: yoshida t. Thorac Cancer. 2020 Dec;11(12):3585-3595. doi: 10.1111/1759-7714.13721. Epub 2020 Oct 27. Thorac Cancer. 2020. PMID: 33108686 Free PMC article.
Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment.
Shirasawa M, Yoshida T, Horinouchi H, Kitano S, Arakawa S, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Kanda S, Watanabe R, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: yoshida t. Br J Cancer. 2021 Mar;124(5):925-932. doi: 10.1038/s41416-020-01188-7. Epub 2020 Nov 30. Br J Cancer. 2021. PMID: 33250511 Free PMC article.
10,980 results
You have reached the last available page of results. Please see the User Guide for more information.